Aug. 14, 2019 - Seeking Alpha
Ruconest appearing to gain market share as the go to acute treatment option, while Takeda and CSL Behring (OTCPK:CSLLY) continue to battle over the prophylactic segment of the HAE market.
Pharming expects continued revenue growth from sales of Ruconest for 2019, especially in the US and Western Europe, with better results in each quarter, compared to the comparable quarter a year earlier.
The ongoing Business Development activities are set to deliver more new products in the near future. Products that can be brought to market through its specialized sales organization, contributing to the company's revenues.
Because of previously described negative outlook on the company's future for their HAE medicine, in September 2018, stock prices fell sharply from its earlier highs. The happening changes in landscape on the HAE playing field that are now working to Pharming's advantage are not yet reflected in its current stock price. As a result, today I see a short-term opportunity to benefit from a sharp increase of the stock value in pursuit of its earlier highs.
Due to its accelerating and expanding platform, sales growth momentum, and an execution-focused management team, I believe Pharming is a very attractive investment opportunity with a potential to more than double its stock price over the mid-term.
Considering the blockbuster potentials in its pipeline, the company may well be marked as a takeover candidate once clinical data starts producing results, in which case the stock price may soar to unforeseen heights, as is no exception in the Biotech/Pharmaceutical industry. This would also be expected to happen, maybe even more so, when the company is allowed to remain independent and start to develop medicines for more 'mainstream' diseases.